Literature DB >> 32765042

Analysis of Comprehensive Pharmacogenomic Profiling of VIP Variants Among the Genetically Isolated Chechen Subpopulation from Jordan.

Laith N Al-Eitan1,2, Doaa M Rababa'h1, Nancy M Hakooz3, Mansour A Alghamdi4,5, Rana B Dajani6,7,8.   

Abstract

BACKGROUND: Profiling rare variants in isolated populations can significantly clarify and understand the development of a clinically relevant process. Therefore, leading to a better identifying novel targeted treatment.
OBJECTIVE: This study aimed to determine the allele frequencies of 56 single nucleotide polymorphisms (SNPs) within several important pharmacogenes.
METHODS: This study consisted of 166 unrelated subjects from a genetically isolated group (Chechen) who were living in Jordan. In this study, the distribution of the variants among Chechen was compared to other ethnic groups available at two databases (Genome 1000 and (ExAC)). The frequency of genotypes and alleles was calculated and tested using the chi-square test and the Hardy-Weinberg equilibrium equation (HWE).
RESULTS: Our results revealed that the distribution of allele frequencies within different pharmacogenes among Chechen showed different similarities with other populations. The CEU and TSI showed the highest resemblance with the Chechen population (75% similarity), in contrast to LWK which had the lowest similarity (30%).
CONCLUSION: This study sheds light on clinically relevant SNPs to enhance medical research and apply pharmacogenomics in clinical settings.
© 2020 AL-Eitan et al.

Entities:  

Keywords:  Phase I enzymes; Phase II enzymes; VIP polymorphism; metabolizing; pharmacogenomics

Year:  2020        PMID: 32765042      PMCID: PMC7368587          DOI: 10.2147/PGPM.S254677

Source DB:  PubMed          Journal:  Pharmgenomics Pers Med        ISSN: 1178-7066


  24 in total

1.  Pharmacogenomics, ethnicity, and susceptibility genes.

Authors:  D W Nebert; A G Menon
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

2.  Breakthrough of the year. Human genetic variation.

Authors:  Elizabeth Pennisi
Journal:  Science       Date:  2007-12-21       Impact factor: 47.728

3.  Genetic Polymorphisms of Pharmacogenomic VIP Variants in the Circassian Subpopulation from Jordan.

Authors:  Laith N Al-Eitan; Namarg N Mohammad; Haneen W Al-Maqableh; Nancy M Hakooz; Rana B Dajani
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731

4.  UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.

Authors:  Nancy Hakooz; Sameh Alzubiedi; Al-Motassem Yousef; Tawfiq Arafat; Rana Dajani; Nidaa Ababneh; Said Ismail
Journal:  Mol Biol Rep       Date:  2012-02-25       Impact factor: 2.316

5.  Population pharmacokinetics and pharmacogenetics of alcohol in Chinese and Indians in Singapore.

Authors:  K Y Seng; L M G Limenta; D Heng; E J D Lee
Journal:  J Clin Pharm Ther       Date:  2012-12-12       Impact factor: 2.512

6.  Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.

Authors:  Pintip Ngamjanyaporn; Ammarin Thakkinstian; Oravan Verasertniyom; Porntip Chatchaipun; Monchand Vanichapuntu; Kanokrat Nantiruj; Kitti Totemchokchyakarn; John Attia; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2010-04-01       Impact factor: 2.631

7.  Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.

Authors:  Daniel Sehrt; Ingolf Meineke; Mladen Tzvetkov; Senol Gültepe; Jürgen Brockmöller
Journal:  Pharmacogenomics       Date:  2011-05-23       Impact factor: 2.533

8.  Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.

Authors:  Kittika Yampayon; Chonlaphat Sukasem; Chanin Limwongse; Yotin Chinvarun; Therdpong Tempark; Ticha Rerkpattanapipat; Pornpimol Kijsanayotin
Journal:  Eur J Clin Pharmacol       Date:  2017-04-08       Impact factor: 2.953

9.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Authors:  Werner Schroth; Lydia Antoniadou; Peter Fritz; Matthias Schwab; Thomas Muerdter; Ulrich M Zanger; Wolfgang Simon; Michel Eichelbaum; Hiltrud Brauch
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

10.  Isolated populations and complex disease gene identification.

Authors:  Kati Kristiansson; Jussi Naukkarinen; Leena Peltonen
Journal:  Genome Biol       Date:  2008-08-26       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.